Kim Hye Kyeong, Kim Taejin
CHA University Fertility Center Ilsan, Goyang-si 10414, Republic of Korea.
Department of Urology, CHA University Ilsan Medical Center, CHA University School of Medicine, Goyang-si 10414, Republic of Korea.
Cells. 2025 Sep 8;14(17):1404. doi: 10.3390/cells14171404.
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, and its incidence is increasing globally. While early-stage ECs generally show good prognosis, advanced or recurrent cases and those with aggressive histologic subtypes exhibit poor outcomes. Traditional histopathologic classification, however, fails to reflect the molecular heterogeneity of EC, limiting its role in guiding treatment. Recent developments in multi-omics have enhanced our understanding of EC biology, which supports more personalized treatment strategies. The Cancer Genome Atlas (TCGA) classification has provided a more systematic molecular framework for stratifying risk and identifying prognostic and therapeutic biomarkers. This review discusses the latest developments in multi-omics-based classification of EC, highlights emerging diagnostic and therapeutic strategies, and summarizes ongoing clinical trials that aim to translate molecular discoveries into improved outcomes.
子宫内膜癌（EC）是发达国家最常见的妇科恶性肿瘤，且其发病率在全球范围内呈上升趋势。虽然早期子宫内膜癌通常预后良好，但晚期或复发病例以及具有侵袭性组织学亚型的病例预后较差。然而，传统的组织病理学分类未能反映子宫内膜癌的分子异质性，限制了其在指导治疗方面的作用。多组学的最新进展加深了我们对子宫内膜癌生物学的理解，这支持了更个性化的治疗策略。癌症基因组图谱（TCGA）分类为风险分层以及识别预后和治疗生物标志物提供了更系统的分子框架。本综述讨论了基于多组学的子宫内膜癌分类的最新进展，强调了新兴的诊断和治疗策略，并总结了旨在将分子发现转化为改善治疗结果的正在进行的临床试验。
